Condition: Non Hodgkin Lymphoma · Sponsor: Miltenyi Biomedicine GmbH
This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.
This description comes directly from the study's public registry record.
Sadie Swift · 617-218-0044 · clinicaltrials@miltenyi.com
Paris Jamiel · 617-218-0044 · clinicaltrials@miltenyi.com
Always discuss trial participation with your own doctor first.
| Stanford University | Stanford, California, United States | Recruiting |
| Yale University | New Haven, Connecticut, United States | Recruiting |
| University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center | Baltimore, Maryland, United States | Not Yet Recruiting |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | Recruiting |
| Froedtert Hospital and the Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06116110